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Purine metabolite levels in preovulatory human follicles
may hold the key to ovarian hyperstimulation syndrome
To the Editor:
We are in agreement with Valerio Napolioni that
adenosine's importance in reproductive biology may be
wider and more variable than the association with energy
charge that we describe. Indeed, we feel that the potent
pharmacology of this purine may be unwelcome under
emerging circumstances. Tremendous progress has been
made in assisted reproductive technology since the birth of
the first baby in 1978 by in vitro fertilization (IVF). The
development of intracytoplasmic sperm injection in the early
1990s further increased the pregnancy and live birth rates
[1]; nonetheless, a serious iatrogenic illness arose from this
technology in the form of ovarian hyperstimulation syn-
drome (OHSS). This is experienced by approximately 5% to
10% of women undergoing IVF; and the clinical symptoms
of OHSS are graded mild, moderate, and severe. Mild
symptoms include abdominal bloating and feeling of
fullness, nausea, diarrhea, and slight weight gain. The
progression to moderate symptoms is defined by excessive
weight gain (weight gain of N2 lb/d), increased abdominal
girth, vomiting, diarrhea, concentrated urine, and excessive
thirst. Severe symptoms are marked abdominal distension
due to ascites, pulmonary edema, and chest pain [2].
The molecular cause of OHSS has been put down to a
soluble factor found to be produced by multiple follicles that
arise as a result of deliberate ovarian stimulation. Research
into follicular fluid has been undertaken in many different
ways: immunoassays for specific molecules or hormones
[3-5], proteomic studies by 2-dimensional electrophoresis
and mass spectrometry analysis [6], and granulosa cell
messenger RNA quantification for inhibin-activin-follistatin
system by polymerase chain reaction [7]. The primary focus
in the search for the molecular agent responsible for OHSS
has centered on vascular endothelial growth factor (VEGF),
perhaps because of our current preoccupation with genes and
proteins rather than smaller potent bioactive molecules.
There is a presumption that VEGF levels are supraphysio-
logic in follicular fluid and will cause local blood vessels to
become leaky [2]. Unfortunately, VEGF levels are not
particularly elevated in follicular fluid compared with other
sources [8]. However, smaller vasodilatory purine metabo-
lites are present in follicular fluid in abundance [9]. In the0026-0495/$ – see front matter © 2010 Published by Elsevier Inc.TE
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1980s, Downs et al [10] studied their roles as meiotic
inhibitors (in mice predominantly). Later, Lavy et al [11],
studying purine metabolite levels in human follicles from
both natural and stimulated cycles, claimed that adenosine
was the inhibitor of human oocyte maturation. In our recent
study, we found that hypoxanthine levels were extremely
variable, but adenosine was a consistent component, and
levels were supraphysiologic—the smaller follicles
contained a much greater concentration of adenosine than
the larger ones [9].
Adenosine's other biological actions make it a significant
contender as the molecular cause of OHSS: adenosine is a
powerful vasodilator; and when administered by intravenous
infusion, it can produce substantial hypotension. Acting via
adenosine A2 receptors, it induces smooth muscle relaxation,
especially in the coronary circulation; but because of its
extremely rapid metabolism, it is very short acting. It is
common practice to infuse adenosine into coronary arteries
when imaging occlusions, but it is not used clinically as a
vasodilator. However, in such patients, most of adenosine's
side effects are related to its vasodilatory properties.
Furthermore, peripheral microvascular endothelia local
production of vascular permeability factor/VEGF A is up-
regulated 2- to 3-fold by adenosine [12].
A wave of symptoms due to vasodilation and increased
vessel permeability spreading from the ovaries to the
abdomen and on to the lungs would be consistent with
unopposed peritoneal infusion of adenosine (leaking from
multiple follicles). This is prevented by adenosine deami-
nase, or ADA (also referred to as adenosine aminohydrolase,
EC 3.5.4.4), a ubiquitous enzyme that appears to be
particularly important in the development of thymocytes.
ADA converts adenosine into inosine through the hydrolysis
of the purine amino group, with an estimated half-life of 1
second (Fig. 1). ADA is present in all tissues, but activity is
particularly high in thymocytes of the thymic cortex. There
are 2 enzymes that carry out ADA activity, called ADA1 and
ADA2. ADA1 a 40-kd monomeric protein with a 200-kd
noncatalytic combining protein, and it is responsible for
about 90% of adenosine deamination. ADA2 is somewhat
larger at 110 kd and appears to play a general adenosine
deamination role in serum. Total absence of ADA activity
results in a form of severe combined immunodeficiency.
However, as pointed out by Valerio Napolioni, polymorphic
variants have now been found with reduced rates of catalytic
activity. In some circumstances, this is positively advanta-
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Fig. 1. Adenosine is deactivated by its rapid conversion to inosine through
the hydrolysis of the purine amino group by ADA.
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geous. Adenosine is released by cardiomyocytes in response
to ischemia and is cardioprotective in this regard [13].
Genotypic variants resulting in reduced metabolism of, or
increased receptor response to, adenosine result in a
phenotypic group more likely to survive ischemic events
[14,15]. The question to be investigated is this: do these
same genotypes result in an IVF patient phenotype prone to
the development of OHSS?
Ray Kruse Iles
Suzanne M. Docherty
Biomedical Sciences
School of Health & Social Science
Middlesex University, Hendon Campus
NW4 4BT The Burroughs, UK
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